Protocol Ledger

NCT03559699 · Phase III · COMPLETED

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Interventional Phase III clinical trial protocol NCT03559699 sponsored by Agios Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-26 Enrollment: 27 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03559699
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)27 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03559699
Protocol FieldVerified Registry Value
NCT IdentifierNCT03559699
Consolidated Lead SponsorAgios Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment27 participants (ACTUAL)
Registered Start Date2018-06-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI